More Restructuring for Merck As Key Product Patents Expire

Facing significant patent cliff pain, Merck said Oct. 1 it plans to refocus its research around new therapies that present the “best opportunities:” vaccines, oncology, diabetes and acute care. The planned restructuring, which also includes job cuts and a new home base address, is intended to adjust to declining sales in asthma and allergy drug Singulair (montelukast sodium) and other Merck products beset by generic competition.
Washington Drug Letter